文献速递临床试验与 GCP

化疗栓塞联合射频消融对比单纯化疗栓塞治疗超出米兰标准可存活肝细胞癌(CERFA):随机对照试验研究方案

Chemoembolization combined radiofrequency ablation vs. chemoembolization alone for treatment of beyond the Milan criteria viable hepatocellular carcinoma (CERFA): study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2023-03-28

本研究为多机构、平行、实用性随机对照试验,计划纳入120例首次TACE后存在存活肿瘤的超米兰标准肝细胞癌患者,随机接受TACE联合RFA或单纯TACE。主要终点为1个月肿瘤反应,次要终点包括无进展生存期、总缓解率、至完全缓解的治疗次数、总生存期及肝功能变化。

要点

  • 超米兰标准肝细胞癌患者首次TACE后存在存活肿瘤者纳入研究。
  • 联合组接受第二次TACE及后续RFA,单药组仅接受第二次TACE。
  • 主要终点为1个月肿瘤反应,次要终点包括生存及肝功能指标。

核心结论

  • 本研究将评估TACE联合RFA治疗中期内更晚期(即超米兰标准)肝细胞癌患者的疗效。

研究设计与样本

  • 多机构、平行、实用性随机对照试验,计划纳入120例超米兰标准肝细胞癌且首次TACE后存在存活肿瘤的患者。
  • 排除转移、血管侵犯或肿瘤直径总和>8 cm的患者。
  • 患者随机分配至TACE联合RFA组或TACE单药组。

主要发现

  • 联合组接受第二次TACE及后续针对存活肿瘤的RFA,单药组仅接受第二次TACE。
  • 两组均在第二次TACE后4-6周行磁共振成像。
  • 主要终点为1个月肿瘤反应,次要终点为无进展生存期、总缓解率、至完全缓解的治疗次数、总生存期及肝功能变化。

局限性

  • 既往评估联合治疗的研究多纳入单个肿瘤直径<5 cm的患者,尚无研究纳入中期但更晚期(即超米兰标准)肝细胞癌患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Many previous studies evaluated a combination of transcatheter arterial chemoembolization (TACE) and radiofrequency ablation (RFA) for treating early hepatocellular carcinoma (HCC); however, studies evaluating combination therapy for beyond-the-Milan criteria HCC are scarce. METHODS: A total of 120 patients with beyond-the-Milan criteria HCC who have viable tumour after first TACE will be enrolled in this multi-institutional, parallel, pragmatic, randomized controlled trial. Patients with metastasis, vascular invasion, or a sum of tumour diameter > 8 cm will be excluded. Eligible patients will be randomly assigned to combination TACE and RFA therapy or TACE monotherapy groups. Patients in the combination therapy group will receive a second TACE and subsequent RFA at the viable tumour. Patients in the TACE monotherapy group will receive only second TACE. Patients in both groups will undergo magnetic resonance imaging 4-6 weeks after second TACE. The primary endpoint is 1-month tumour response, and secondary endpoints are progression-free survival, overall response rate, number of treatments until CR, overall survival, and change in liver function. DISCUSSION: Although TACE can be used to treat intermediate-stage HCC, it is difficult to achieve CR by first TACE in most intermediate-stage patients. Recent studies show a survival advantage of combination therapy over monotherapy. However, most studies evaluating combination therapy included patients with a single tumour sized < 5 cm, and no studies included patients with intermediate-stage but more advanced (i.e., beyond-the-Milan criteria) HCC. This study will evaluate the efficacy of combined TACE and RFA therapy for patients with advanced HCC within the intermediate stage. TRIAL REGISTRATION: Clinical Research Information Service (CRiS) KCT0006483.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Lee SK, Yang H, Kwon JH, et al. Chemoembolization combined radiofrequency ablation vs. chemoembolization alone for treatment of beyond the Milan criteria viable hepatocellular carcinoma (CERFA): study protocol for a randomized controlled trial. Trials. 2023. PMID: 36978150. doi:10.1186/s13063-023-07266-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。